Compare RMBS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBS | ABVX |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.2B |
| IPO Year | 1997 | N/A |
| Metric | RMBS | ABVX |
|---|---|---|
| Price | $114.28 | $120.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $102.00 | ★ $130.09 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 02-02-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.64 | N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $678,488,000.00 | $6,231,374.00 |
| Revenue This Year | $29.03 | $6.80 |
| Revenue Next Year | $16.19 | N/A |
| P/E Ratio | $54.88 | ★ N/A |
| Revenue Growth | ★ 31.05 | N/A |
| 52 Week Low | $40.12 | $4.77 |
| 52 Week High | $135.75 | $148.83 |
| Indicator | RMBS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 61.41 | 48.89 |
| Support Level | $88.50 | $113.64 |
| Resistance Level | $135.75 | $125.86 |
| Average True Range (ATR) | 6.43 | 7.91 |
| MACD | 2.40 | -0.48 |
| Stochastic Oscillator | 54.73 | 56.80 |
Rambus Inc is a semiconductor solutions provider offering high-speed, high-security computer chips and Silicon intellectual property. The company's key products include memory interface chips, built for high speed and efficiency; silicon IP, providing high-speed memory and chip-to-chip connection technology; and architecture licenses, which allow customers to use portions of Rambus' patented inventions for their own digital electronics. The firm receives the majority of its revenue from the United States, Taiwan, Asia, Japan, and Singapore.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.